Previous close | 3.6200 |
Open | 3.4500 |
Bid | 3.3500 |
Ask | 3.5500 |
Strike | 100.00 |
Expiry date | 2025-01-17 |
Day's range | 3.3600 - 3.4500 |
Contract range | N/A |
Volume | |
Open interest | 1.58k |
Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. Novo Nordisk's popular obesity drug Wegovy and Eli Lilly's in demand Zepbound are GLP-1 drugs. Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.